CHO CLD is a time and resource intensive process. While new vectors and robotics have improved timelines and throughput, they are costly and haven’t solved the core productivity limits of traditional CHO hosts. To address this, we have developed CHOZN® Elite cell line, a production-adapted CHO cell line that delivers high-yield clones using standard plasmids and media — no expensive technology required. Clones from minipool and bulk pool workflows reached up to 13 g/L and 5 g/L respectively with the later attainable in only 80 days. Depending on the CLD method used, this new host cell line meets industrial needs by accelerating the CLD or increasing the titer leading to cost-saving process.
In this webinar, you will learn about:
- Traditional CLD is slow, costly, and limited by CHO host performance
- CHOZN® Elite cell line enables high productivity using standard tools — no expensive tech needed.
- How to save cost by achieving 13g/L in a minipool clone, using a standard plasmid.
- Speeding up the CLD process by achieving 5 g/L in a bulk pool clone in only 80 days.
Speaker
Mike Johns
Merck
Senior Scientist in Cell Lines R&D
Mike Johns is a senior scientist on the Expression Systems and Novel Biopharmaceutical Materials team at Merck. Since joining the team in 2014, Mike has been instrumental in advancing biopharmaceutical development through his expertise in CHO cell line engineering, high throughput assay development, and the integration of artificial intelligence and machine learning (AI/ML) into cell line development workflows. His work focuses on improving the efficiency and predictability of bioproduction processes, leveraging data-driven approaches to accelerate timelines, and enhance product yields.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
期间:1h
语言:English
场次 1:Thu, October 16, 2025 4:00 PM CEST
如要继续阅读，请登录或创建帐户。
暂无帐户？